![](https://www.diabetesnews.com/wp-content/uploads/2012/09/Expiry-drugs1-150x150.jpg)
Yesterday, the FDA’s Endocrinologic & Metabolic Drug Advisory Committee voted to recommend approval for degludec, a new long acting insulin for the treatment of type 1 and type 2 diabetes.
Read more
Yesterday, the FDA’s Endocrinologic & Metabolic Drug Advisory Committee voted to recommend approval for degludec, a new long acting insulin for the treatment of type 1 and type 2 diabetes.
Read more